Cardiac rehabilitation

Western Canada's Largest Heart Health Prevention Clinic Launches the AI Heart Scanner

Retrieved on: 
Thursday, October 5, 2023
Diamond, Diagnosis, Cardiac rehabilitation, Inflammation, Cardiology, AB, Living Archives on Eugenics in Western Canada, Artificial intelligence, Rehabilitation, Data analysis, Patient, Pain, Medical device, Medical imaging

CALGARY, AB, Oct. 5, 2023 /CNW/ - Heart Fit Clinic, Western Canada's leading cardiac rehabilitation, and heart attack and stroke prevention centre, is proud to announce the launch of the groundbreaking AI Heart Scanner.

Key Points: 
  • CALGARY, AB, Oct. 5, 2023 /CNW/ - Heart Fit Clinic, Western Canada's leading cardiac rehabilitation, and heart attack and stroke prevention centre, is proud to announce the launch of the groundbreaking AI Heart Scanner.
  • The AI Heart Scanner represents a significant milestone in the field of heart disease prevention, rehabilitation, and diagnosis.
  • "We are thrilled to be at the forefront of heart health advancements by introducing the AI Heart Scanner," states Diamond Fernandes, Founder and Director of Heart Fit Clinic.
  • To learn more about Heart Fit Clinic and the AI Heart Scanner, please visit www.heartfit.ca .

EQS-News: Affluent Medical Presents Poster on First Successful Procedure with Epygon at the 2023 CSI Conference in Frankfurt

Retrieved on: 
Wednesday, June 28, 2023
Moyamoya disease, Heart, NYHA, Suture, Tricuspid valve, CSI, Diabetes, Cardiac rehabilitation, EACTS, Echocardiography, LVEF, Health status of Asian Americans, Minerva, Valve, Infarction, Euronext Paris, Mitral regurgitation, Patient, Mitral valve, Risk, CEST, Annual general meeting, European Association for Cardio-Thoracic Surgery, Aix-en-Provence, III, Medtech, New York Heart Association Functional Classification, Safety, Urinary incontinence, Medical device

Abstract Title: TRANSCATHETER MITRAL VALVE IMPLATATION WITH THE EPYGON PROSTHESIS: FIRST-IN-HUMAN

Key Points: 
  • Abstract Title: TRANSCATHETER MITRAL VALVE IMPLATATION WITH THE EPYGON PROSTHESIS: FIRST-IN-HUMAN
    “We are excited to inform the specialist audience about the first successful procedure with our Epygon system,” said Dr. Christophe Giot, Vice President Clinical Affairs.
  • “Our device is the only biomimetic transcatheter cardiac mitral valve in development that mimics the native mitral valve and physiological blood flow.
  • The objective of the study is to evaluate the safety and efficacy of Epygon valve implantation at 30 days.
  • Affluent Medical anticipates presenting interim results from the first five patients of the Minerva pilot study at the Annual Meeting of the European Association for Cardio-Thoracic Surgery (EACTS) in October 2023.

NorthShore - Edward-Elmhurst Health and Motiv Launch Nation's First In-Home Virtual Cardiac Recovery Program with Integrated Behavioral Health Support

Retrieved on: 
Wednesday, June 7, 2023
Exercise, American Heart Association, Cardiac rehabilitation, Health, Overalls, Fear, Rehabilitation, Emotion, North, Medicare, MD, Patient, Access, Risk, CVI, Genetic testing, Diagnosis, Wellness, Nursing, Hospital, Medical device, Motivational interviewing

EVANSTON, Ill., June 7, 2023 /PRNewswire/ -- NorthShore – Edward-Elmhurst Health (NS-EEH), the third-largest health system in Illinois serving 1.5 million patients across Chicagoland, and Motiv, an emerging cardiology care innovator, today announced the co-development of the first in-home virtual cardiac recovery program with integrated behavioral health support. The program addresses challenges associated with traditional cardiac rehabilitation (rehab) by providing a more personalized and convenient approach, including one-on-one health coaching and behavioral health support.

Key Points: 
  • The program addresses challenges associated with traditional cardiac rehabilitation (rehab) by providing a more personalized and convenient approach, including one-on-one health coaching and behavioral health support.
  • The opportunity will be offered to patients who have experienced a cardiac event and indicate potential benefit from participation in the post-discharge in-home virtual cardiac recovery program.
  • A personalized program created by a Clinical Exercise Physiologist with Health & Wellness Coaching certification who serves as the patient's Health Coach throughout the program.
  • The in-home virtual cardiac recovery program is the latest innovation offered through the NorthShore Cardiovascular Institute (CVI).

The Inner Circle Acknowledges, Kenneth Bescak, MD, F.A.C.C., as a Distinguished Top Pinnacle Professional for his contributions to the Medical Field

Retrieved on: 
Friday, May 19, 2023
Verde Valley, Ohio State University, Heart failure, Internal medicine, American Heart Association, Cardiac rehabilitation, American College of Cardiology, American Board of Internal Medicine, Cardiovascular disease, National Lipid Association, Multimedia, Private practice, Inner circle, Heart Failure Society of America, American College of Physicians, American Board of Commissioners for Foreign Missions, Patient, Cardiology, American College of Chest Physicians, American College, Medical specialty, Raffles Medical Group, Medical device, Physician, MD, Cottonwood

COTTONWOOD, Ariz., May 18, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Kenneth Bescak, MD, F.A.C.C., is acknowledged as a Top Pinnacle Professional for his contributions to the Medical Field.

Key Points: 
  • COTTONWOOD, Ariz., May 18, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Kenneth Bescak, MD, F.A.C.C., is acknowledged as a Top Pinnacle Professional for his contributions to the Medical Field.
  • Dr. Bescak began his medical educational journey from Ohio State University, Columbus where he received his medical degree.
  • An exemplary diagnostic cardiologist, Dr. Bescak is one of only 500 board-certified lipidologists in the U.S. and one of only seven in Arizona.
  • He was also honored as a distinguished Fellow of the American College of Cardiology and the American College of Chest Physicians.

UCARDIA ANNOUNCES ACQUISITION OF PHAS3; LAUNCHES CARDIOLOGIST PRACTICE REMOTE PATIENT MONITORING OFFERING

Retrieved on: 
Monday, May 8, 2023
Heart, Cardiovascular disease, Health, Acquisition, Patient, CVD, Software, Cardiology, Education, Self-management, Cardiac rehabilitation, Hospital, Medical device, Nursing

This acquisition will result in a comprehensive, market-leading solution for providers, payers, and consumers, covering all facets of cardiac rehabilitation, conditioning, and remote monitoring for patients affected by cardiovascular disease (CVD).

Key Points: 
  • This acquisition will result in a comprehensive, market-leading solution for providers, payers, and consumers, covering all facets of cardiac rehabilitation, conditioning, and remote monitoring for patients affected by cardiovascular disease (CVD).
  • Ucardia and Phas3 will continue to support all existing customers and their patients in the companies' joint portfolio and are excited to begin planning exciting new products and services that take advantage of their combined strengths.
  • Jointly with this acquisition, Ucardia is announcing its newest offering, Ucardia-at-Home, a comprehensive remote patient monitoring platform that enables cardiologists and physician practices to enhance the monitoring, engagement, education, and self-management of patients between traditional doctor visits and close the gap in patient care management.
  • "We believe in extending access to every patient who needs this essential care."

Affluent Medical : Very positive results one month after Epygon mitral heart valve implantation in a first patient.

Retrieved on: 
Monday, April 17, 2023
Moyamoya disease, Heart, NYHA, Mitral regurgitation, Suture, Diabetes, Hospital, Cardiac rehabilitation, EACTS, Echocardiography, Safety, Health status of Asian Americans, Clinical trial, Pathology, Minerva, Doctor of Philosophy, Infarction, Data, Incidence, MD, Patient, Risk, Mitral valve, WHO Global Preparedness Monitoring Board, Regulatory News Service, ISIN, Tricuspid valve, Death, Aix-en-Provence, III, Medtech, New York Heart Association Functional Classification, Urinary incontinence, Medical device, Dentistry, Medical imaging, Science

Affluent Medical : Very positive results one month after Epygon mitral heart valve implantation in a first patient.

Key Points: 
  • Affluent Medical : Very positive results one month after Epygon mitral heart valve implantation in a first patient.
  • Very positive outcome at one month follow-up of the patient implanted with the Epygon mitral valve.
  • Less than 4% of patients with severe heart mitral insufficiency receive surgery, according to Affluent Medical estimates.
  • It is the only biomimetic cardiac mitral valve in development, mimicking the native mitral valve and physiological blood flow.

Affluent Medical : Affluent Medical announces initial success of first clinical implantation of its Epygon mitral heart valve via minimally invasive route

Retrieved on: 
Thursday, March 16, 2023
Medtech, HCL, Urinary incontinence, Heart, Anatomy, Regulatory News Service, Mitral regurgitation, Cardiac rehabilitation, Hospital, Aix-en-Provence, Risk, Trial of the century, Pathology, Infarction, Death, Cardiac surgery, ISIN, Patient, Minerva, Science, Moyamoya disease, Mitral valve, Incidence, Princeton University Department of Psychology, Safety, Doctor of Philosophy, Rapids, Tricuspid valve, Diabetes, Proctor, Wealth, Medical device, Medical imaging, Dentistry, MD

Epygon is the only biomimetic mitral valve to restore the physiological blood vortex.

Key Points: 
  • Epygon is the only biomimetic mitral valve to restore the physiological blood vortex.
  • Rapid, 15 minutes, valve implantation procedure and early hospital discharge of the patient on day 5.
  • It is the only biomimetic cardiac mitral valve under development, mimicking the native mitral valve function and generating a physiological blood flow.
  • From initial hands-on the Epygon transcatheter device to deploying the valve inside the patient’s heart, it took me only 15 minutes.

SCAD Survivor Finds Support, Treatment with Texas Health Resources

Retrieved on: 
Thursday, March 9, 2023
Life, Texas Health Arlington Memorial, Texas Health Resources, Death, Ortenberg, Risk, Cardiac rehabilitation, SCAD, Medicine, Dietary supplement, Employment agency, Hospital

She sought treatment at Texas Health Arlington Memorial Hospital and Texas Health Harris Methodist Hospital Fort Worth for spontaneous coronary artery dissection, or SCAD.

Key Points: 
  • She sought treatment at Texas Health Arlington Memorial Hospital and Texas Health Harris Methodist Hospital Fort Worth for spontaneous coronary artery dissection, or SCAD.
  • "Mrs. Robinson's condition is quite serious, because it can happen more than once, and it has," said Joseph Ortenberg, M.D., a cardiologist on the Texas Health Fort Worth medical staff and with Texas Health Heart and Vascular Specialists, a Texas Health Physicians Group practice*.
  • Robinson found support through cardiac rehabilitation at Texas Health Arlington Memorial.
  • *Providers employed by Texas Health Physicians Group are not employees or agents of Texas Health Resources hospitals.

Allegheny Health Network Cardiovascular Institute Completes 500th Heart Transplant

Retrieved on: 
Wednesday, February 15, 2023
Libin Cardiovascular Institute, Joint Commission, CVI, Caregiver, Division, AGH, Mother, Life, Physician, Hospital, Allegheny, Transplant, Cardiac rehabilitation, AHN, LVAD, 500th, Allegheny General Hospital, Spouse, AUC, Patient, Pulmonary hypertension, CORE, Ann Harrison (lung transplant recipient), Friends, Heart failure, Mortality, Allegheny Health Network, Survival, Heart, Gold Seal Winery, Nursing, Father, Gold Seal, Dentistry, Medical device, Education, MD

PITTSBURGH, Feb. 15, 2023 /PRNewswire-PRWeb/ -- Allegheny Health Network's (AHN) Cardiovascular Institute reached a significant milestone in cardiac transplantation when heart failure specialists and cardiothoracic surgeons, led by Candice Lee, MD, performed the 500th heart transplant at Allegheny General Hospital (AGH) in Pittsburgh on Saturday, January 14. The patient, Keith Lowry, 68, of Dunbar, Pa is recovering well from the procedure.

Key Points: 
  • PITTSBURGH, Feb. 15, 2023 /PRNewswire-PRWeb/ -- Allegheny Health Network's (AHN) Cardiovascular Institute reached a significant milestone in cardiac transplantation when heart failure specialists and cardiothoracic surgeons, led by Candice Lee, MD , performed the 500th heart transplant at Allegheny General Hospital (AGH) in Pittsburgh on Saturday, January 14.
  • Our recent milestone is a testament to the flexibility and skill of our coordinators, nurses, and physicians, and our partners at the Center for Organ Recovery and Education," said Stephen Bailey, MD , heart transplant surgeon and chair of AHN Cardiovascular Institute.
  • The heart transplant program at AGH was developed beginning in 1985, under the clinical direction of George J. Magovern Jr., MD, cardiothoracic surgeon.
  • A key factor in AGH's impressive transplant survival rate is the post-operative care management provided by the transplant center's cross-specialty heart failure team.

Casana Sustains Accelerated Momentum Ahead of Desired Product FDA Clearance

Retrieved on: 
Tuesday, January 24, 2023
Trial of the century, Regulatory affairs, University of Massachusetts, Caregiver, Blood pressure, Quality assurance, Massachusetts General Hospital, Physician, Cardiac rehabilitation, Partnership, FDA, ...Continued, Teodoro Casana Robles, EMR, Federal Food, Drug, and Cosmetic Act, Growth, Medtech, Hypertension, AARP, Research, Heart rate, Pharmaceutical industry, Management

ROCHESTER, N.Y., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Casana, the leader in smart toilet heart health monitoring, announced today a catalyst year of advancement while pursuing FDA clearance for the firm’s first product, The Heart Seat™. After securing $30 million in Series B funding last January, bringing the firm’s total capital to $46 million, Casana experienced more than double the growth in personnel, research partners, and FDA clearance milestones in 2022.

Key Points: 
  • ROCHESTER, N.Y., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Casana, the leader in smart toilet heart health monitoring, announced today a catalyst year of advancement while pursuing FDA clearance for the firm’s first product, The Heart Seat™.
  • After securing $30 million in Series B funding last January, bringing the firm’s total capital to $46 million, Casana experienced more than double the growth in personnel, research partners, and FDA clearance milestones in 2022.
  • Casana is seeking their 510k clearance from the FDA in hopes of initial product launch by the end of 2023.
  • Casana has also grown an additional remote-workforce nationwide, accounting for 30% of the organization’s overall labor force.